Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $93.59 on Wednesday. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The company has a market cap of $53.89 billion, a price-to-earnings ratio of 53.79, a PEG ratio of 2.31 and a beta of 0.85. The firm has a 50 day simple moving average of $88.38 and a 200 day simple moving average of $84.20.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the business earned $0.67 earnings per share. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Robert W. Baird raised their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Edwards Lifesciences by 27.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after buying an additional 23,514 shares during the period. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $803,686,000. TD Asset Management Inc increased its stake in shares of Edwards Lifesciences by 6.4% in the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after acquiring an additional 47,051 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Edwards Lifesciences by 22.2% during the 4th quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock valued at $5,912,000 after acquiring an additional 12,591 shares during the period. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Edwards Lifesciences during the fourth quarter worth $1,626,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.